Company: Chameleon Biosciences
Job title: Founder & Chief Executive Officer
I founded Chameleon Biosciences in 2017 to provide next-generation gene therapies to treat more patients with rare genetic diseases. I combined my immunology and gene therapy backgrounds to engineer a next generation AAV based vector for systemic repeat dosing. I have more than 20 years of experience in the biotechnology industry, primarily in the area of gene therapy. Seven of the gene therapies I have worked on have been or are currently in clinical trials, 4 in late-stage or pivotal clinical trials. In March 2019 Chameleon closed our seed round of funding to establish lab operations to produce product that is now being tested in multiple animal models.
Prior to founding Chameleon, I was the Director of Analytics at Audentes Therapeutics where I focused on developing gene therapies for Myotubular Myopathy, Pompe Disease, and CASQ2-related Catecholaminergic Polymorphic ventricular tachycardia (CPVT). While at BioMarin, I was a Lead Scientist playing a key role in testing and process development for a Hemophilia A gene therapy product. Before moving to BioMarin, I was instrumental in developing the testing strategies, characterization and process development of Lentiviral-based gene therapies for Cerebral Adrenoleukodystrophy, Sickle Cell Anemia and Beta Thalassemia as a scientist at BlueBird Bio. I began my gene therapy career while at Cell Genesys by contributing to early CAR-T programs.